ArticleInternational urology and nephrology2026
Association of the newly proposed dietary index for gut microbiota and chronic kidney disease.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
backgroundAlterations of the gut microbiota play a key role in the pathogenesis and progression of chronic kidney disease (CKD), and their importance is becoming more widely recognized. However, the relationship between the Dietary Index for Gut Microbiota (DI-GM) and the prevalence of CKD has not been fully investigated.
methodsThis study employed data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018, which included 24,962 people, following the DI-GM's eligibility requirements. This study's statistical methodologies included multivariable logistic regression, restricted cubic splines (RCS), subgroup analysis, and interaction tests.
resultsOf the 24,962 participants, 4,342 had CKD, representing 17.39% of all participants. The prevalence of CKD exhibited an inverse relationship with CKD, low estimated glomerular filtration rate (low-eGFR), and albuminuria. Specifically, for every one-unit rise in DI-GM, there was a corresponding 5% reduction in CKD prevalence (OR 0.95, 95% CI 0.93 ~ 0.97). In addition, the strength of association between DI-GM and decreased renal function (OR = 0.92, 95% CI 0.89 ~ 0.95) was higher than that of albuminuria (OR = 0.96, 95% CI 0.93 ~ 0.98). Further analysis using RCS indicated a linear association between DI-GM and CKD, low-eGFR, and albuminuria. Moreover, subgroup evaluations revealed that this negative association between DI-GM and CKD, low-eGFR, and albuminuria remained statistically significant in most subgroups.
conclusionOur research revealed a negative correlation between DI-GM and CKD, low-eGFR, and albuminuria in American adults. This finding suggests that DI-GM may serve as a useful tool to help raise awareness among individuals at high risk for CKD.
Indexed as
Identifiers
41014435What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.